Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Do FDA Submission, Approval Declines Outside Cancer Signal Future Treatment Gaps?

Executive Summary

Outlining a "fairly substantial decline in the number of non-oncology NMEs approved compared to last year" plus downward trend in applications, US FDA's Jenkins underscores continued "tremendous needs" for primary care products.


Related Content

NME Mid-Year Report: Approvals Might Near Record With Strong 2nd Half
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
Keeping Track: CDER 2016 Novel Approvals Hold At 22 As US FDA Declines Cempra's Solithera
Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
Jenkins' Retirement From US FDA Was Several Years In The Making
What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down
FDA New Drug Approval Count May Fall Back To Earth In 2016
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts